In contrast to a potential oncogenic role of HAS enzymes in carcinogenesis, HAS3 under-expression was a poor prognositic marker for bladder cancer [15] and the promoter methylation of HAS3 was recently proposed to regulate hyaluronan production in pancreatic cancer [16]. Here, HAS3 is linked to urinary bladder cancer.